Cim LLC Acquires Shares of 90,821 ADMA Biologics Inc $ADMA

Cim LLC bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 90,821 shares of the biotechnology company’s stock, valued at approximately $1,654,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. SVB Wealth LLC acquired a new stake in ADMA Biologics during the 1st quarter worth $35,000. Cullen Frost Bankers Inc. increased its stake in ADMA Biologics by 112.5% in the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,081 shares during the period. Toth Financial Advisory Corp raised its holdings in shares of ADMA Biologics by 1,081.6% in the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 2,293 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of ADMA Biologics during the second quarter worth about $46,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of ADMA Biologics by 161.4% during the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,493 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Down 2.9%

Shares of NASDAQ:ADMA opened at $19.78 on Friday. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The firm’s 50-day simple moving average is $16.47 and its 200-day simple moving average is $17.26. The company has a market cap of $4.71 billion, a price-to-earnings ratio of 23.00 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. The firm had revenue of $134.22 million during the quarter, compared to the consensus estimate of $131.20 million. During the same quarter last year, the firm earned $0.15 earnings per share. The firm’s revenue was up 12.0% compared to the same quarter last year. As a group, equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $28.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.